Giuseppe Minniti: Gliofocus Phase 3 Trial Explores PARP Inhibitors with Radiotherapy in GBM
Giuseppe Minniti, Radiation Oncologist at Sapienza University of Rome, shared a post on X by ESTRO, adding:
“The importance of combining PARP inhibitors with radiation therapy is currently being evaluated in Gliofocus phase 3 trial by Ivy Brain Tumor Center testing RT and Niraparib for MGMT unmethylated GBM.”
Quoting ESTRO‘s post:
“Long-term results from the RADIOPARP Phase I Trial: Safety and radiosensitization of Olaparib with radiotherapy in triple-negative breast cancer patients, published in the Red Journal.
Read it before your patients.”
Title: Safety and Potential Radiosensitizing Effect of Olaparib in Combination With Breast Radiation Therapy for Patients With Triple-Negative Breast Cancer With Residual Disease: Long-Term Results From the RADIOPARP Phase 1 Trial
Journal: Red Journal
Authors: Pierre Loap, Delphine Loirat, Marc-Henri Stern, Jean-Yves Pierga, Kim Cao, Anne Vincent-Salomon, Frederique Berger, Alain Fourquet, Youlia Kirova
More posts featuring Giuseppe Minniti on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023